Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Kezar Life Sciences, Inc. < Previous 1 2 Next > Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference January 04, 2023 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) December 07, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022 November 14, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) November 11, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update November 10, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Life Sciences to Participate in Two Upcoming Investor Conferences November 09, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting November 03, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting October 14, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) October 06, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis October 03, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 September 29, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) September 02, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update August 11, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) August 03, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position July 11, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Life Sciences to Present at the William Blair Biotech Focus Conference July 07, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) July 06, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis June 27, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) June 03, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update May 12, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) May 05, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis May 03, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) April 15, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update March 17, 2022 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis November 15, 2021 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Life Sciences to Present at the Jefferies London Healthcare Conference November 11, 2021 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Reports Third Quarter Financial Results and Provides Business Update November 09, 2021 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar to Host Virtual Investor and Analyst Day on November 15, 2021 November 03, 2021 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor Malignancies October 27, 2021 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs October 05, 2021 From Kezar Life Sciences, Inc. Via Business Wire Tickers KZR < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.